Stocktoria
HERON THERAPEUTICS, INC. /DE/ HRTX
HERON THERAPEUTICS, INC. /DE/ (HRTX) earns a Piotroski F-score of 2/9 (weak financial health). It does not currently pay a dividend. FY2025 revenue was $154.9M at a -13.0% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -2.37 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 2/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| HRTX | HERON THERAPEUTICS, INC. /DE/ | 2/9 | — | — | +7.4% |
| LQDA | Liquidia Corp | 3/9 | -4.36 | — | +1031.2% |
| MGNX | MACROGENICS INC | 2/9 | -12.89 | — | -0.3% |
| ELTP | ELITE PHARMACEUTICALS INC /NV/ | 6/9 | 7.73 | 9.5 | +77.1% |
| KPTI | Karyopharm Therapeutics Inc. | 2/9 | — | — | +0.6% |
| SNDX | Syndax Pharmaceuticals Inc | 1/9 | -7.54 | — | +627.8% |
| PHAT | Phathom Pharmaceuticals, Inc. | 4/9 | — | — | +216.9% |
About HERON THERAPEUTICS, INC. /DE/
Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. Heron Therapeutics, Inc. was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. The company was founded in 1983 and is headquartered in Cary, North Carolina.
FAQ
Is HRTX financially healthy?
HERON THERAPEUTICS, INC. /DE/'s Piotroski F-score is 2/9 (8–9 is excellent, 0–3 weak).
Does HRTX pay a dividend?
No, HERON THERAPEUTICS, INC. /DE/ does not currently pay a dividend.
How profitable is HRTX?
In FY2025, HERON THERAPEUTICS, INC. /DE/ had a net margin of -13.0% and a return on equity of -140.9%.
What is the analyst price target for HRTX?
The average Wall-Street price target for HERON THERAPEUTICS, INC. /DE/ is $2.00, about 486.7% above the recent price, from 1 analysts (consensus: buy).
Is HRTX a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on HERON THERAPEUTICS, INC. /DE/: a Piotroski F-score of 2/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.